Perinatal Asphyxia, HIE Sarnat Staging, and Therapeutic Hypothermia Protocol

Etiology and Pathophysiology of Perinatal Asphyxia

Hypoxic-Ischemic Encephalopathy (HIE) is a devastating neurological syndrome resulting from acute impairment of placental gas exchange or umbilical perfusion, leading to systemic hypoxemia, hypercapnia, and metabolic acidosis.

Perinatal Sentinel Events

Perinatal asphyxia frequently occurs as a consequence of catastrophic acute intrapartum events:

• Placental Disruptions: Severe abruptio placentae, extensive placenta previa with hemorrhage.
• Umbilical Cord Emergencies: Cord prolapse, true tight cord knot, cord avulsion, tight nuchal cord with vascular occlusion.
• Uterine and Maternal Complications: Uterine rupture (most common in women undergoing trial of labor after previous caesarean delivery), amniotic fluid embolism, maternal cardiorespiratory arrest, profound systemic hypotension.
• Fetal Factors: Ruptured vasa praevia, massive fetomaternal hemorrhage, acute twin-to-twin transfusion.

The Biphasic Cascade of Hypoxic-Ischemic Injury

Brain injury in HIE does not occur as a single static event, but evolves dynamically across three distinct pathological phases:

[Acute Intrapartum Insult]
            |
Primary Energy Failure (Intrapartum)
- ATP depletion, Na+/K+ pump failure
- Cytotoxic edema, membrane depolarization
- Glutamate excitotoxicity & Ca2+ influx
            |
Resuscitation & Reperfusion
            |
Latent Phase (Hours 0 - 6)
- Transient recovery of cerebral oxidative metabolism
- The "Therapeutic Window" (Cooling Must Begin)
            |
Secondary Energy Failure (Hours 6 - 48)
- Mitochondrial failure & Cytochrome c release
- Apoptosis, oxidative stress, microglial activation
- Clinical & electrographic seizures
            |
Tertiary Phase (Weeks - Months)
- Chronic neuroinflammation, glial scarring, dysmyelination

1. Primary Energy Failure:
   • Occurs during the acute hypoxic-ischemic insult itself.
   • Cessation of cerebral blood flow and oxygen delivery depletes high-energy phosphates (ATP and phosphocreatine). Without ATP, the energy-dependent Na+/K+ ATPase membrane pumps fail, causing intracellular sodium, water, and chloride accumulation, resulting in cytotoxic edema.
   • Neuronal membrane depolarization triggers massive presynaptic release of excitatory amino acids, particularly glutamate, while energy-dependent reuptake transporters are blocked.
   • Glutamate overactivates postsynaptic NMDA (N-methyl-D-aspartate) and AMPA receptors, precipitating a lethal intracellular influx of calcium.
   • Intracellular calcium overload activates calpains, caspases, phospholipases, endonucleases, and neuronal nitric oxide synthase, leading to acute necrotic cell death.
2. The Latent Phase (The Therapeutic Window):
   • Following successful delivery room resuscitation and restoration of cerebral perfusion, cerebral oxidative metabolism transiently and partially recovers.
   • Cellular high-energy phosphates normalize, and cytotoxic edema temporarily improves.
   • This latent phase lasts about 1–6 hours. Although the infant appears relatively stable biochemically, downstream apoptotic cascades are primed.
   • The Critical Window for Hypothermia: Therapeutic hypothermia must be initiated strictly within 6 hours of birth during this latent window to halt downstream neurodestructive cascades before the secondary phase commences.
3. Secondary Energy Failure:
   • Initiates between 6 and 48 hours post-insult.
   • Characterized by secondary mitochondrial permeabilization with opening of the mitochondrial permeability transition pore (MPTP), leakage of cytochrome c into the cytoplasm, and activation of caspase-3 apoptotic cascades.
   • Marked by excessive production of reactive oxygen species (ROS), peroxynitrite radicals, microglial neuroinflammation, and secondary cytotoxic edema.
   • Clinically, this phase is marked by progressive neurological deterioration, brain swelling, and the emergence of severe clinical and electrographic seizures.
4. Tertiary Phase:
   • Extends for weeks to months post-insult, involving ongoing low-grade neuroinflammation, astrogliosis, microglial persistence, and impaired oligodendroglial maturation with deficient myelination.

---

Neonatal Drug Withdrawal: An Important Differential

Neonatal opioid withdrawal follows prenatal opioid exposure and may cause irritability, tremor, increased tone, high-pitched crying, disturbed sleep, poor feeding, vomiting or diarrhoea and poor weight gain. Onset depends on the drug and can be delayed with longer-acting opioids. Consider sepsis, hypoglycaemia, hypocalcaemia and brain injury when assessing these signs; exposure history alone does not establish the diagnosis. Use serial structured assessment, such as Finnegan scoring or the functional Eat, Sleep, Console approach. Initial care emphasises supported rooming-in when medically appropriate, low stimulation, safe soothing and feeding/growth support. Persistent functionally important withdrawal despite these measures may require neonatal-supervised oral morphine or methadone with gradual weaning. Arrange family support, a safe discharge plan and developmental follow-up.

Source: Canadian Paediatric Society 2025 neonatal withdrawal guidance.

---

Clinical Staging: Sarnat and Sarnat Classification

Developed in 1976 and modified for modern clinical cooling trials, the Sarnat staging system stratifies neonatal encephalopathy into three clinical stages, correlating directly with electroencephalographic findings and neurodevelopmental outcomes.

---

Therapeutic Hypothermia Protocol: Eligibility and Initiation

Therapeutic hypothermia is the standard of care for moderate-to-severe HIE. Major multicenter trials (TOBY, CoolCap, NICHD, ICE) and Cochrane systematic reviews confirmed that therapeutic hypothermia significantly reduces the combined risk of death or severe neurodevelopmental disability at 18 to 24 months (relative risk ~0.75; Number Needed to Treat [NNT] = 6 to 7), with persistent neurocognitive benefits demonstrated at school age (6 to 8 years).

Inclusion Criteria (ILCOR / European Guidelines)

To qualify for therapeutic hypothermia, the neonate must meet Criteria A, B, and C:

• Criterion A (Gestational Maturity): Gestational age ≥36 completed weeks AND birth weight ≥1,800 g.
• Criterion B (Objective Evidence of Perinatal Asphyxia): At least ONE of the following:
  1. 10-minute Apgar score ≤5.
  2. Continued requirement for positive pressure ventilation or endotracheal intubation at 10 minutes of life.
  3. Severe metabolic acidosis on umbilical cord arterial blood or any neonatal blood sample within 60 minutes of birth: pH ≤7.00 OR base deficit ≥16 mmol/L.
• Criterion C (Neurological Encephalopathy Assessment): Clinical moderate-to-severe encephalopathy or the seizure criterion is required:
  1. Moderate to severe encephalopathy (Sarnat Stage 2 or 3) demonstrated by abnormalities in at least 3 of 6 clinical categories:
     • Level of consciousness
     • Spontaneous activity
     • Posture
     • Muscle tone
     • Primitive reflexes (suck or Moro)
     • Autonomic system (pupils, heart rate, or respirations)
  2. Confirmed clinical or electrographic seizures.

Obtain aEEG/EEG promptly to support assessment and detect seizures. An abnormal background alone does not replace clinical evidence of significant encephalopathy, and unavailable monitoring must not delay cooling when the clinical criteria are clearly met.

Exclusion Criteria

• Postnatal age >6 hours at cooling initiation.
• Known major lethal chromosomal abnormality (e.g., trisomy 13 or 18) or major congenital brain malformations.
• Intractable systemic hemorrhage refractory to blood component replacement.
• Moribund infant where redirection to palliative comfort care has been decided.

Cooling Implementation

• Target Temperature: Core body temperature maintained strictly at 33.5°C (acceptable range: 33.0°C to 34.0°C).
• Modality: Total body cooling using a servo-controlled thermal mattress with circulating fluid, guided by a continuous indwelling rectal probe (inserted 5 cm) or esophageal temperature sensor.
• Duration: Exactly 72 hours of maintenance hypothermia.

---

Controlled Rewarming Protocol and Hazards

Following the completion of 72 hours of hypothermia, rewarming must be executed with extreme vigilance.

Rewarming Specifications

• Rewarming must be slow and controlled at a rate not exceeding 0.5°C per hour.
• At 0.5°C per hour, warming from 33.5°C to 36.5°C takes about 6 hours; slower protocols take longer.
• Continuous core temperature monitoring must continue throughout rewarming and for at least 24 hours post-rewarming to prevent rebound pyrexia.

---

Bedside Neuromonitoring and Seizure Management

Continuous neurophysiological monitoring is indispensable during therapeutic hypothermia and rewarming.

Amplitude-Integrated EEG (aEEG)

Single- or dual-channel aEEG provides continuous bedside tracking of cerebral background voltage:

• Continuous Normal Voltage (CNV): Continuous background activity with lower margin >5 µV and upper margin >10 µV. Associated with favorable neurodevelopmental prognosis.
• Discontinuous Normal Voltage (DNV): Discontinuous background with lower margin <5 µV and upper margin >10 µV. Indicates moderate cerebral depression.
• Burst Suppression (BS): Periods of very low voltage (<2 µV) interspersed with high-amplitude bursts (>25 µV). Indicates severe encephalopathy.
• Continuous Low Voltage (CLV): Continuous low-amplitude background with upper margin <10 µV and lower margin <5 µV.
• Flat Trace (FT): Isoelectric trace with background constantly below 5 µV. Strongly predictive of fatal outcome or severe disability.
• Sleep-Wake Cycling (SWC): Characterized by periodic broadening and narrowing of the aEEG bandwidth. The return of SWC within 36 to 48 hours is an excellent prognostic marker.

Electroclinical Dissociation

Between 50% and 70% of neonatal seizures in encephalopathic infants are purely electrographic without overt motor movements. Furthermore, administration of sedatives or initial antiepileptic drugs often abolishes clinical motor manifestations while electrical cortical seizure activity persists unabated (electroclinical uncoupling). Continuous aEEG or multichannel video-EEG is therefore mandatory.

Antiseizure Drug Protocol

1. First-Line: Phenobarbital, administered at a loading dose of 20 mg/kg IV infused slowly over 20 minutes. If seizures persist, an additional dose of 10 to 20 mg/kg may be given (up to a cumulative maximum of 40 mg/kg).
2. Second-Line: Levetiracetam (40 to 60 mg/kg IV) or Phenytoin / Fosphenytoin (20 mg PE/kg IV over 20 minutes under continuous ECG monitoring).
3. Refractory Seizures: Consider a midazolam infusion (0.1–0.4 mg/kg/hour) under intensive monitoring. Lidocaine is an alternative with continuous cardiac monitoring, but is contraindicated after phenytoin/fosphenytoin or in neonates with cardiac disease; dosing must account for therapeutic hypothermia.

---

Systemic Complications and Supportive Care During Cooling

Therapeutic hypothermia impacts multiple organ systems, requiring meticulous intensive care:

• Cardiovascular: Sinus bradycardia (heart rate typically 80 to 100 beats/min) is a normal, expected physiological response to hypothermia that reduces myocardial metabolic work. It does not require pacing or inotropes unless systemic perfusion is compromised or heart rate falls below 60 beats/min. Maintain mean arterial pressure (MAP) >40 mmHg.
• Renal and Fluid Balance: Acute tubular necrosis and syndrome of inappropriate ADH secretion (SIADH) are common. Restrict initial maintenance fluids to 40 to 50 mL/kg/day and monitor urine output and daily electrolytes.
• Hematological: Mild thrombocytopenia and prolonged coagulation times (PT/aPTT) occur because hypothermia inhibits the enzymatic kinetics of clotting cascade proteins.
• Dermatological: Subcutaneous fat necrosis manifests 1 to 6 weeks after cooling as firm, indurated, erythematous or violaceous subcutaneous nodules over bony pressure areas (shoulders, buttocks). Clinicians must monitor for late-onset hypercalcemia, which can cause nephrocalcinosis and cardiac arrhythmias.

---

Neuroimaging and Prognostication

Cranial Ultrasound (CUS)

Performed on day 1 of life primarily to rule out pre-existing antenatal brain injury (e.g., porencephaly, established ventriculomegaly, or germinal matrix hemorrhage) that would contraindicate cooling. Serial Doppler examination of the anterior cerebral artery evaluates the Resistive Index (RI):

$RI = \frac{\text{Peak Systolic Velocity} - \text{End Diastolic Velocity}}{\text{Peak Systolic Velocity}}$

A low RI <0.55 can reflect cerebral vasodilation and is associated with adverse outcome, but its predictive value is reduced during therapeutic hypothermia. Interpret it as one part of the clinical, EEG and MRI assessment.

Brain Magnetic Resonance Imaging (MRI)

Brain MRI is the gold standard diagnostic and prognostic imaging modality in neonatal HIE.

• Optimal Timing: Postnatal Day 4 to 7 (after completion of 72 hours of hypothermia and rewarming, within the first week of life).
  • Why not Day 1–2? Diffusion-Weighted Imaging (DWI) abnormalities are still evolving and can underestimate the full spatial extent of cytotoxic injury.
  • Imaging After the First Week: Diffusion abnormalities may pseudo-normalize over the following days, including around days 8–12 in cooled infants. Conventional T1/T2 imaging and MRS remain useful; repeat MRI at 10–14 days can clarify an uncertain early scan or a mismatch with the clinical course.

Major MRI Topographical Patterns of Injury

1. Basal Ganglia and Thalamus (BGT) Pattern:
   • Mechanism: Result of acute, profound, total asphyxial events (sentinel disasters such as uterine rupture or complete cord prolapse).
   • Involvement: Selectively damages metabolically active deep gray matter nuclei: the ventrolateral thalami, posterior putamen, and perirolandic sensorimotor cerebral cortex.
   • The PLIC Sign: In healthy term neonates, the posterior limb of the internal capsule (PLIC) exhibits high signal intensity (hyperintensity) on conventional T1-weighted MRI due to mature myelination. Loss of this normal high T1 signal intensity in the PLIC is an important marker of adverse motor outcome. Assess it with the distribution and severity of other MRI lesions, MRS where available, the neurological examination and EEG evolution when counselling about prognosis.
2. Watershed (Parasagittal / Border-Zone) Pattern:
   • Mechanism: Result of prolonged, partial, insidious asphyxia accompanied by systemic hypotension.
   • Involvement: Affects the vascular watershed regions located between the anterior, middle, and posterior cerebral artery territories, damaging the parasagittal cerebral cortex and subcortical white matter.
   • Outcome: Typically spares the basal ganglia; associated with cognitive impairment, speech and language deficits, and visual-spatial dysfunction, with relatively preserved gross motor capabilities.